José L Güell (Instituto Microcirugía Ocular of Barcelona, Barcelona, Spain) discusses the continuous development into IOLs, including EDOF and trifocal lenses, and lenses used to adjust different errors of refraction and special cases. The main limitation in the current treatment is the final placement of the lens, and current and future research into adjustable lenses and using femtosecond lasers to correct the refractive error once the lens is inside the eye.
1. What have been the most significant recent developments in the area of IOLs? (0:35)
2. Discuss the current unmet needs and/or the challenges you face when treating patients with cataracts. (1:29)
3. What developments are you most excited about in the area of cataract surgery over the next few years? (2:53)
4. Which presentations/data have interested you the most at this year’s WOC? (3:57)
Share this Video
Related Videos In Refractive Surgery
Mitchell A Jackson, Hawaiian Eye and Retina 2023: Intraocular lens exchange – surgical pearls
It was a pleasure to have the opportunity to meet with Dr Mitchell A Jackson (Jacksoneye, Lake Villa, IL, USA) who shared surgical pearls from his presentation, on successful IOL exchange with an open capsule. Questions: What risks are associated with intraocular lens (IOL) exchange with an open capsule? (0:19) What […]
Mitchell A Jackson, Hawaiian Eye and Retina 2023: Challenges for ophthalmic surgeons
We were delighted to speak with Dr Mitchell A Jackson (Jacksoneye, Lake Villa, IL, USA) on his views about the main challenges faced by ophthalmic surgeons today, and common reasons for IOL exchange. Questions: 1. What are the biggest challenges facing ophthalmologic surgeons today? (0:19) 2. What are the most common reasons for intraocular lens […]
Pilocarpine hydrochloride ophthalmic solution 1.25%: An innovative prescription eye drop for the treatment of presbyopia
Video abstract delivered by Dr Selina McGee (BeSpoke Vision, Edmond, OK, USA) for the article: McGee S, Waring GO, Pilocarpine hydrochloride ophthalmic solution 1.25%: an innovative prescription eye drop for the treatment of presbyopia. touchREVIEWS in Ophthalmology. 2022;16(2):54–62 DOI: https://doi.org/10.17925
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!